ACC - Fundamentals of auditing and business
ACC311ACC501
ACF - (Accounting And Finance Related)
ACF619ACFI619
COM - (Commerce Related)
COM619COMI619
ECO - (Economics Related)
ECO401 ECO402 ECO403 ECO404
ENG - (English Related)
ENG001 ENG101 ENG201 ENG301 ENG401
ETH201 - Ethics (for Non-Muslims)
ETH201
ISL201 - Islamic Studies
ISL201
IT - (Info Tech Related
IT000IT0001IT430IT619ITI619
MIS - (Project And Internship Report)
MIS619 MISI619MIS620 MISI620
PAD - (Public Administration Related)
PAD619 PADI619
PAK301 - Pakistan Studies
PAK301PAK302
PHY - (Physics Related)
PHY101 PHY301
PSC201 - International Relations
PSC201PSC401
SOC - (Socialogy Related)
SOC101 SOC401
STA - (Statistics and Research)
STA301 STA630
URDU - (Urdu Related)
URD101
VUPROJECTS
AIOU PROJECTS
VUDESK TUBE
VUDESK APP
IT INTERNSHIPS FB Page
FB Group
DESK MEMBERS

APPLY NOW  | SIT (STEP IN SECURITY) | Ghrapical Password | Smart ETL Tool | SMS BLOCKER

Chinese Scientists Will Begin First Human CRISPR Gene-Editing Trial

A group of Chinese scientists will be the first in the world to use the CRISPR-Cas9 gene-editing technology on humns in a clinical trial set to begin next month.

The team plans to start by testing cells in people with lung cancer, the science journal Nature reported. The trial received approval from the ethical review board at Sichuan University’s West China Hospital in Chengdu on July 6.

CRISPR is a powerful technology that has the potential to change human lives by allowing scientists to remove or edit genetic mutations responsible for incurable diseases.

The Chinese trial will include patients with metastatic non-small cell lung cancer and who have not seen success from chemotherapy, radiation therapy and other treatments.

“Treatment options are very limited,” Lu You, an oncologist leading the trial team, told Nature. “This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day.”

Other teams have run human clinical trials using a different gene-editing technique.

A team in the United States is also planning a human clinical trial that would use CRISPR-Cas9 to treat cancer. The National Institutes of Health approved that project last month, Nature reported at the time, but it still needs the U.S. Food and Drug Administration and a university review board to sign off. U.S. researchers said they expect that trial could begin by the end of 2016.

Online printing services
Booklet printing

Views: 82

Comment

Join Virtual University Desk for comments and conversations

Join Virtual University Desk

Super Active Members 

Sponsers

VUDESK GROUPS

 

© 2019   Created by ʭIsmail Shahʭ.   Powered by

Badges  |  Report an Issue  |  Terms of Service